Mantle Cell Lymphoma (MCL) (BSH 2018 & 2018)

t(11;14) --> overexpression of Cyclin D1--> deregulation of cell cycle at G1-S phase boundary

Immunohist: Cyclin D1+, BCL2+, SOX11+, BCL6-

Flow: CD19+, CD20+, CD5+, FMC7+, Surface Ig+, CD10-, CD23-, CD200-



3-10% of NHL

Median age 60-65 years old

Male > Female

Worst features of low and high grade lymphoma. Incurable by standard therapy

Median survival 4-5 years in all comers (8-12 years in younger, fitter patients)

CNS relapse occurs in 4-8% - usually leptomeningeal and within 2 years


Clinical Presentation

>90% present with Stage 3-4 disease

Splenomegaly, bone marrow infiltration and leukaemic involvement are common

30-50% of patients have >2 extranodal sites involved – esp. GI and liver

Variable clinical course – aggressive blastoid variant or indolent disease




  • Excision or core biopsy, or peripheral blood flow if leukaemic


  • Small to intermediate sized cells with irregular, cleaved nuclei


  • CD19+, CD20+, CD5+, FMC7+, Surface Ig+

  • CD10-, CD23-, CD200-


  • Ki67 proliferation index is a prognostic factor (>30% correlates w/ poor outcomes)

  • Immunohisto: Cyclin D1+, BCL2+, SOX11+, BCL6-


  • t(11;14)(q13;q32), can be detected by FISH

  • TP53 mutation predicts a very poor outcome


Aberrant phenotype – many variants including cyclin D1 neg, CD10 pos or CD5 neg


Cyclin D1 Negative MCL – genuine cases do occur, typically will be SOX11+


MCL in situ – syn. Mantle Cell Neoplasia – CD5+, Cyclin D1+ small lymphocytes in the mantle zone of follicles in morphologically reactive lymph nodes. Low risk of progression to clinical disease.


Differential Diagnosis of Cyclin D1+ haem malignancies:

  • Hairy Cell Leukaemia

  • Myeloma

  • Diffuse Large B Cell Lymphoma





  • FBC, Film, Flow cytometry

  • U&E, LFT, LDH

  • HIV, Hep C/B (for Rituximab)

  • Bone marrow biopsy – may be omitted if periph. blood involvement present. Trephine not required if particulate aspirate for flow.

  • +/- CSF flow and morphology



  • CT N-P +/- MRI brain if CNS involvement suspected.

  • PET-CT not routinely recommended as not shown to upstage patients compared to CT



  • Microscopic presence of MCL in GI tract found in 92% of cases

  • However, rarely changes management

  • Perform upper and lower endoscopy if GI bleeding or Stage 1a disease and curative radiotherapy is being considered.


Prognostic Scores

MIPI (Mantle Cell IPI), sMIPI and MIPI-c all provide prognostic information but do not currently affect treatment decisions.




1st Line Management


Lack of definitive data

Enroll in clinical trial where possible


Stage I/IIa

  • May be treatable with localized involved field radiotherapy alone (60-80% CR w/ possible cure)

  • Include endoscopy in staging investigations if considering RT alone


Stage III/IV, Indolent Disease

  • Can W&W closely, defers treatment by median of 12 months

  • Indications to treat include: Bulky LN, B symptoms, Symptomatic organomegaly, BM failure


Stage III/IV, Fit

  • R-Maxi-CHOP/cytarabine (NORDIC Protocol) --> Autograft in 1st CR

  • R-DHAP x4 (LyMa Trial) --> Autograft in 1st CR

  • Autograft significantly prolongs PFS, not clear that it improves OS.

  • R-maintenance post autograft 2-monthly for 3 years

    • Proven benefit after R-CHOP / R-DHAP (4-year PFS 85% / OS 89% vs 64/80% w/out)


Stage III/IV, Older/Less fit

  • Consider using Cumulative Illness Rating Scale (CIRS) to aid assessment of elderly patients

  • R-CHOP / R-Bendamustine / VR-CAP

  • R-maintenance 2-monthly until progression (funding restricts to a maximum 2 years)

    • Proven benefit post R-CHOP with prolonged PFS (and OS in some studies)

    • No benefit demonstrated post R-Benda


CNS Prophylaxis?

  • Conflicting data on the benefit of CNS prophylaxis. BSH guidelines conclude unable to make a recommendation, but suggest consider its use in young patients with blastoid morphology.


Assessing Treatment Response


Assess response with an end of treatment CT Neck-Pelvis


End of treatment PET-CT may have prognostic significance but does not affect management decisions and so not currently recommended.


Minimal residual disease (MRD) monitoring of t(11;14) by PCR may predict relapse but is not currently in routine use.


2nd line management


Excluding transplant, 1st relapse has median survival of 1-2 years

No standard second line treatment

Fit patients should be considered for RIC allograft in 2nd remission



  • Approved by NICE for 2nd line in combination with rituximab (but not 3rd)

  • Most active single agent in relapsed MCL – 68% response rate, 21% CR.

  • Also shown efficacy in CNS relapse

  • 2016 trial ibrutinib vs temsirolimus – ibrutinib showed better PFS, no OS advantage



  • R-CHOP / R-Benda / R-BAC, whichever not used previously

  • Trial: BTK Inhibitors

  • Bortezomib, Temsirolimus & lenalidomide are all licensed for relapsed MCL

  • Venetoclax looks active in phase 1 trial



  • Autograft prolongs disease response but no significant OS benefit yet shown

  • MRD monitoring post-autograft predicts relapse